---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-009140"
form_type: "8-K"
ticker: "CBIO"
cik: "0001253689"
company_name: "CRESCENT BIOPHARMA, INC."
filed_at: "2024-06-13T23:59:59+00:00"
generated_at: "2026-06-01T04:32:56.120373+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# GlycoMimetics grants performance-based stock options to NEOs vesting on FDA approval of uproleselan

## Summary
- CEO Harout Semerjian granted 521,250 shares; CFO Brian Hahn and CMO Edwin Rock each granted 187,500 shares.
- Options have exercise price of $0.2589 per share and vest upon FDA approval of uproleselan for AML.
- Awards are in addition to service-based options granted Jan 12, 2024 with exercise price of $3.11 per share.
- Vesting is contingent on continued service through the FDA approval date.

## SEC filing metadata
- accession: 0001558370-24-009140
- form_type: 8-K
- ticker: CBIO
- cik: 0001253689
- company_name: CRESCENT BIOPHARMA, INC.
- filed_at: 2024-06-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1253689/000155837024009140/0001558370-24-009140-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1253689/000155837024009140/glyc-20240610x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-009140
- JSON: https://secwatch.observer/filing/0001558370-24-009140.json
- Plain text: https://secwatch.observer/filing/0001558370-24-009140.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.